Objective To discuss the influence of hydrotherapy on jaundice of newborn. Methods We divided 400 newborn into the hydrotherapy group and the control group with 200 cases in each group randomly. The newborn in the hydrotherapy group received hydrotherapy from 24 hours to 30 days after born,one time per day and 15 minutes per time.The control group was given pure shower, the time of first defecation ,the time of meconinm turning yellow, jaundice index and incidence of hyperbilirubinemia were compared at the 1st,5th,10th and 30th days after born. Results The time of first defecation and the time of meconium turning yellow were advancer in the observation group than those in the control group(P<0.01 ).The jaundice index at the 5th,10th andf 30th days after born and the incidence of hyperbilirubinemia also decreased in the observation group compared with those of the control group (P<0.01 ). Conclusion Hydrotherapy could decrease the jaundice of newborn and prevent the incidence of kernicterus.

Extended-field and subtotal nodal radiation therapy (RT),developed in the 1960 s,was first reliably curative treatment for early-stage Hodgkin lymphoma (HL). However, the large volume of normal tissue irradiated resulted in significant delayed toxicity, including cardiac disease and second cancers (SC).The 30-year cumulative incidence of heart disease among adult survivors receiving 40-45 Gy of extended-field or mantle RT is approximately 30 ％; the incidence of SC is similar. How to improve disease control while reducing the toxicity of treatment has been a major objective of HL trials. Contemporary involved-field RT (IFRT) and involved-node RT (INRT) reduces irradiated volumes and produces significant reductions in normal tissue dose, and response-adapted therapy may be a means of identifying those patients most likely to benefit from treatment reduction or intensification, and enhanced screening will facilitate early intervention to reduce the clinical burden of late effects. There is a increasing interest in elucidating the genetic correlation of treatment toxicity.

The limited-Hodgkin lymphoma (HL) treatment most preferred combined modality treatment,there are some scholars believe that nonbulky stage Ⅰ,Ⅱ of good prognosis HL patients,ABVD chemotherapy alone is acceptable,radiation therapy alone for stage Ⅰ or limited stage Ⅱ nodular lymphocytepredominant HL patients.Individual treatment by easing speed adjustment treatment in the future may make patients more benefit.

Accurate imaging of lymphoma is essential for optimal management. Positron emission tomography(PET-CT),by providing both anatomic and functional information,is fundamentally altering staging,monitoring of response,response assessment,and choice of treatment modality for lymphomas, including Hodgkin lymphoma. This imaging technique, when used carefully in conjunction with standard testing,increases the sensitivity of lesion detection, provides an opportunity to monitor the quality of response during treatment, permits separation of fibronecrotic scartissue from viable tumor, and adds prognostic information.PET-CT has become integral to modern lymphoma management, but as a relatively new diagnostic technique,it is still being studied and neither its full potential nor its major limitations are fully understood. Discussed herein are recent observations from clinical trials and single-center experiences with PET-CT to explore its advantages and limitations from a clinician’ s point of view.

T-cell lymphoma is a rare form of non-Hodgkin lymphoma with high heterogeneity. The basic and clinical research of T cell lymphoma is lagged than B cell lymphoma. Recently, with the development of pathology and molecular biology, the level of diagnose has been raised, novel therapies such as targeted therapy and immunotherapy have been developed, these will make it possible to improve the prognosis of patients.

Advanced-stage Hodgkin's lymphoma (HL) has become a curable disease in the majority of patients.ABVD is considered to be the standard therapy,but debates continue regarding the role of radiation therapy(RT)in this patient population. The incorporation of interim positron emission tomography (PET) imaging, and characterization of HL on cellular and molecular levels are emerging as tools for treatment stratification and predictors of disease status. Therapeutic advances over the past 3 decades have resulted in the cure of the majority of the patients with advanced-stage HL.Several questions have emerged when considering what constitutes optimal therapy with a balance between a high cure rate and minimizing shortand long-term toxicity.This review focuses on 3 key elements:what is the optimal chemotherapy? What is the role of radiation therapy(RT)in advanced HL? Can therapy based on clinical biological risk factors be adapted?

Primary testicular lymphoma (PTL) is an uncommon extranodal lymphoma,with an aggressive clinical course and poor outcome.A combined treatment with full-course anthracycline-based chemotherapy with rituximab and central nervous system prophylaxis with intrathechal methotrexate and contralateral testicular radiotherapy should be considered as the standard of care at limited stage.These patients have a very high risk of central nervous system recurrence and the addition of systemic central nervous system prophylaxis with intravenous methotrexate may be the best treatment option.Primary central nervous system lymphoma (PCNSL) is an aggressive disease with a dismal prognosis,particularly when treated with established protocols used for systemic non-Hodgkin lymphoma.Use of methotrexate in combination with cytarabine has been proposed as a standard induction regimen.The role of the anti-CD20 antibody has not yet been defined,however,phase Ⅰ and Ⅱ trials suggest its efficacy despite low penetration within the cerebrospinal fluid.High-dose chemotherapy followed by autologous stem cell transplantation has shown high remission rates with 3-year overall suvival rates of up to 87 ％.

Multiple myeloma (MM) is malignant plasma cell clonal disease.Autologous stem cell transplantation (ASCT) strengthen the advantages of the high-dose chemotherapy in treatment of MM,which achieves long-term survival in some patients.Even in the era of targeted novel agents,ASCT can still obviously increase the response rate of treatment.To improve the therapeutic efficacy,targeted novel agents were administrated before and after ASCT.However,targeted novel agents still cannot replace ASCT therapy in the treatment of MM.The direction of future research is to find more reasonable,effective and low toxic treatment.

The patients of chronic lymphocytic leukemia(CLL)have great individual differences.It is important for clinicians to determine the prognosis at the beginning of diagnosis and choose proper treatment for the patients.The recent advances in biological prognostic indicators of CLL were reviewed,including IgVH gene mutation status,ZAP70,CD_(38),chromosome abnormality[t(11q;v),del(11q),del(17p),+12 and del(13q)].telomere and telomerase.

The Hodgkin and Reed/Sternberg (HRS) tumor cells of classical Hodgkin's lymphoma (HL) and the lymphocyte-predominant (LP) tumor cells of nodular lymphocyte-predominant HL are both derived from germinal center B cells.Several studies show that HL pathogenesis includes the deregulated activity of numerous members and regulators of the NF-κB and JAK/STAT signaling pathways,genetic lesions of epigenetic regulators,and the interactions between tumor cells and other infiltrating cells in the microenvironment,et al.